Serostim injections are quick and simple. It is administered subcutaneously just underneath the skin. This type of injection is less penetrating than directly into a vein or muscle (intravenous or intra muscular injections).
Serostim is generally well tolerated when taken as prescribed. In clinical studies, 1.5% of patients stopped using Serostim due to drug-related side effects. The most common reactions to Serostim
Serostim must be given with antiviral therapy. There is no evidence of HIV replication with Serostim therapy in the presence of any nucleoside analogues in vitro. In the controlled clinical trials, no significant growth hormone increase in viral burden was observed. However, growth hormone has been shown to increase HIV replication in some experiments.
Serostim therapy should be carried out under the regular guidance of a physician who is experienced in the diagnosis and management of AIDS. Inadequate nutritional intake, malabsorption and hypogonadism (common in individuals with AIDS and contribute to catabolism and weight loss) should also be monitored. Patients should contact their physician if they experience any side effects during treatment with Serostim. Serostim should generally not be used in patients with acute critical illness in intensive care units
Rebuilding and retaining lean body mass is possible with Serostim treatment. Muscle, organ tissue and body fluids are components of lean body mass. However, the impact of treatment-induced improvements in body weight and lean body mass has not been established in placebo-controlled trials.